XML 40 R14.htm IDEA: XBRL DOCUMENT
v3.19.3

Goodwill and Intangible Assets | 9 Months Ended
--- | ---
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | Goodwill and Intangible Assets The following sets forth the goodwill and intangible assets by major asset class:
|  |  | September 30, 2019 |  | December 31, 2018
| Useful Life (Yrs) | Gross |  | Accumulated Amortization |  | Net Book Value |  | Gross |  | Accumulated Amortization |  | Net Book Value
Indefinite lived: |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill(a) |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |
Definite lived: |  |  |  |  |  |  |  |  |  |  |  |  |
Patents | 8 – 17 |  | 5,802,528 |  |  | (5,787,384 | ) |  | 15,144 |  |  | 5,802,528 |  |  | (5,742,079 | ) |  | 60,449 |
Licenses | 8 – 17 |  | 1,323,761 |  |  | (1,240,917 | ) |  | 82,844 |  |  | 1,323,761 |  |  | (1,219,357 | ) |  | 104,404 |
CELLECTRA®(b) | 5 – 11 |  | 8,106,270 |  |  | (7,999,501 | ) |  | 106,769 |  |  | 8,106,270 |  |  | (7,679,190 | ) |  | 427,080 |
GHRH(b) | 11 |  | 335,314 |  |  | (327,392 | ) |  | 7,922 |  |  | 335,314 |  |  | (303,630 | ) |  | 31,684 |
Bioject(c) | 2 – 15 |  | 5,100,000 |  |  | (2,102,222 | ) |  | 2,997,778 |  |  | 5,100,000 |  |  | (1,882,222 | ) |  | 3,217,778 |
Other(d) | 18 |  | 4,050,000 |  |  | (3,300,000 | ) |  | 750,000 |  |  | 4,050,000 |  |  | (3,131,250 | ) |  | 918,750 |
Total intangible assets |  |  | 24,717,873 |  |  | (20,757,416 | ) |  | 3,960,457 |  |  | 24,717,873 |  |  | (19,957,728 | ) |  | 4,760,145 |
Total goodwill and intangible assets |  |  | $ | 35,231,244 |  |  | $ | (20,757,416 | ) |  | $ | 14,473,828 |  |  | $ | 35,231,244 |  |  | $ | (19,957,728 | ) |  | $ | 15,273,516 |
(a) | Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.
(b) | CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX.
(c) | Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.
(d) | Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.
Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2019 was $267,000 and $800,000, respectively. Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2018 was $267,000 and $983,000, respectively. Estimated aggregate amortization expense is $267,000 for the remainder of fiscal year 2019, $547,000 for 2020, $520,000 for 2021, $493,000 for 2022, $276,000 for 2023 and $1.9 million for 2024 and subsequent years combined.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration